Synthesis and Biological Evaluation of a New Biphenyl-Based Organogold(III) Complex with In Vitro and In Vivo Anticancer Activity
Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 1755-1771
DOI: 10.1021/acs.jmedchem.4c02470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 10.01.2025. Verfasst von Edwyn Remadna und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, CNRS Institut Parisien de Chimie Moléculaire, IPCM, F-75005 Paris, France. Hauptthemen laut MEDLINE: Antineoplastic Agents, Biphenyl Compounds, Apoptosis, Organogold Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: Institut National de la Sant? et de la Recherche M?dicale, Centre National de la Recherche Scientifique, Minist?re de l'Enseignement sup?rieur et de la Recherche.
Abstract (Originalsprache)
Despite recent advances in cancer treatment, there is still a need for novel compounds with antineoplastic activity. Among 11 biphenyl-based organogold(III) N-heterocyclic carbene (NHC) (BGC) complexes of general formula [(C^C)Au(NHC-pyr)X], where (C^C) = 4,4'-ditertbutylbiphenyl, X = Cl or phenylacetylide, and (NHC-pyr) is a pyridyl-substituted NHC ligand, the complex BGC4 bearing a 4-CF3-pyridyl substituent and a chloride ligand showed promising antineoplastic activity on the triple negative breast cancer cell line. BGC4 was able to induce cell apoptosis but had no effect on the cell cycle. In vivo, BGC4 reduced the tumor growth rate by increasing the necrosis area and decreasing the mitotic activity. Repeated injections of BGC4 did not induce common side effects. The present investigation shows that BGC4 is a promising antineoplastic candidate. Its potential as a future chemotherapy for the treatment of cancer will be strengthened by evaluating its efficacy in combined treatment with current chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sorbonne Université, CNRS Institut Parisien de Chimie Moléculaire, IPCM, F-75005 Paris, France.
- Université Paris Cité, INSERM, Health & Functional Exposomics - HealthFex, U1124, Saint Germain des Prés Campus, 75006, Paris, France.
- Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, 38106 Braunschweig, Germany.
- Department of Pathology, Saint-Antoine Hospital, AP-HP, Sorbonne Université, 75012 Paris, France.
- Sorbonne Université, OSU Ecce Terra, F-75005 Paris, France.
- Institut des Sciences de la Terre de Paris (ISTeP), Sorbonne Université, CNRS-INSU, F-75005 Paris, France.
ORCID-Profile: Serge Thorimbert, Benoît Bertrand
Förderung
- Institut National de la Sant? et de la Recherche M?dicale
- Centre National de la Recherche Scientifique
- Minist?re de l'Enseignement sup?rieur et de la Recherche
- Sorbonne Universit?
- Universit? Paris-Cit?
Zitieren
APA
Remadna, E., Wilsmann, A., Stadler, N., Forté, J., Hoyeau, N., Ott, I., Noël, J., Caron, B., Thorimbert, S., Forgez, P., & Bertrand, B. (2025). Synthesis and Biological Evaluation of a New Biphenyl-Based Organogold(III) Complex with In Vitro and In Vivo Anticancer Activity. Journal of Medicinal Chemistry, 68(2), 1755-1771. https://doi.org/10.1021/acs.jmedchem.4c02470
Vancouver
Remadna E, Wilsmann A, Stadler N, Forté J, Hoyeau N, Ott I, et al. Synthesis and Biological Evaluation of a New Biphenyl-Based Organogold(III) Complex with In Vitro and In Vivo Anticancer Activity. Journal of Medicinal Chemistry. 2025;68(2):1755-1771. doi:10.1021/acs.jmedchem.4c02470
BibTeX
@article{Remadna2025,
author = {Remadna, Edwyn and Wilsmann, Anna and Stadler, Nicolas and Forté, Jérémy and Hoyeau, Nadia and Ott, Ingo and Noël, Julie and Caron, Benoît and Thorimbert, Serge and Forgez, Patricia and Bertrand, Benoît},
title = {Synthesis and Biological Evaluation of a New Biphenyl-Based Organogold(III) Complex with In Vitro and In Vivo Anticancer Activity},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {2},
pages = {1755--1771},
doi = {10.1021/acs.jmedchem.4c02470}
}
EUVIMED